Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 13/20 | 0.50 |
| ▸ | GIPR | P48546 | 12/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | MPL | P40238 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585770 | 0.90 | GCGR (0.50) | GCGRGIPR | |
| SCHEMBL5585837 | 0.89 | HDAC3 (0.48) | GCGRGIPRKDM4EMAPTMAPK1 | |
| SCHEMBL5585589 | 0.81 | HDAC3 (0.49) | GCGRGIPRKDM4EMAPTMAPK1 | |
| SCHEMBL5585738 | 0.80 | HDAC3 (0.48) | GCGRGIPRKDM4EMAPTMAPK1 | |
| SCHEMBL5585683 | 0.79 | GCGR (0.47) | GCGRGIPRKDM4EMCHR1 | |
| SCHEMBL5585930 | 0.78 | HDAC3 (0.46) | GCGRGIPRKDM4EMAPTMAPK1 | |
| SCHEMBL5585521 | 0.77 | GCGR (0.46) | GCGRGIPRKDM4E | |
| SCHEMBL5585531 | 0.77 | GCGR (0.40) | GCGRGIPRMAPT | |
| SCHEMBL5585451 | 0.77 | GCGR (0.45) | GCGRGIPRKDM4E | |
| SCHEMBL5585566 | 0.77 | NFKB1 (0.59) | GCGRGIPRKDM4EMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20050065196-A1 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1452530-A1 | AZOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065196-A1 | Azole compound and medicinal use thereof | PTPN7, PTPN1, PTPN5 | GCGR 317/4885GIPR 195/4885KDM4E 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.